Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX)‘s stock had its “sector perform” rating restated by analysts at Royal Bank Of Canada in a report released on Friday. They presently have a C$39.00 target price on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price objective indicates a potential upside of 60.49% from the stock’s previous close.

A number of other research analysts also recently issued reports on VRX. Scotiabank decreased their price objective on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a “sector perform” rating for the company in a report on Monday, July 25th. TD Securities reiterated a “buy” rating and set a C$38.00 price objective on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, August 10th.

Shares of Valeant Pharmaceuticals Intl (TSE:VRX) traded down 0.04% on Friday, hitting $24.29. The stock had a trading volume of 1,086,774 shares. Valeant Pharmaceuticals Intl has a 52 week low of $18.41 and a 52 week high of $165.77. The stock’s 50-day moving average price is $28.03 and its 200 day moving average price is $32.34. The company’s market cap is $8.44 billion.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.